#### UNITED STATES BANRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK

In re:

PURDUE PHARMA L.P., et al.,

Debtors.1

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

EIGHTH INTERIM FEE APPLICATION OF PJT PARTNERS LP AS INVESTMENT BANKER TO THE DEBTORS AND DEBTORS-IN-POSSESSION FOR ALLOWANCE OF COMPENSATION FOR SERVICES RENDERED AND FOR THE REIMBURSEMENT OF ALL ACTUAL AND NECESSARY EXPENSES INCURRED FOR THE PERIOD OF FEBRUARY 1, 2022 THROUGH APRIL 30, 2022

#### **SUMMARY SHEET**

PJT Partners LP Name of Applicant:

Authorized to Provide

Professional Services to: **Debtors** 

Date of Retention: Order entered on January 9, 2020 approving the

retention of PJT Partners LP nunc pro tunc to

September 15, 2019 [Docket No. 728]

Period for Which Compensation

and Reimbursement is Sought: February 1, 2022 through April 30, 2022

Amount of Compensation Sought

as Actual, Reasonable, and Necessary: \$675,000.00

Amount of Expense Reimbursement Sought

as Actual, Reasonable, and Necessary: \$397.71

Amount of Cash Payment Sought: \$675,397.71

<sup>&</sup>lt;sup>1</sup> The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 2 of 50

This is a \_\_\_ monthly \_\_x interim \_\_\_ final application

## UNITED STATES BANRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK

In re:

PURDUE PHARMA L.P., et al.,

Debtors.1

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

EIGHTH INTERIM FEE APPLICATION OF PJT PARTNERS LP AS INVESTMENT BANKER TO THE DEBTORS AND DEBTORS-IN-POSSESSION FOR ALLOWANCE OF COMPENSATION FOR SERVICES RENDERED AND FOR THE REIMBURSEMENT OF ALL ACTUAL AND NECESSARY EXPENSES INCURRED FOR THE PERIOD OF FEBRUARY 1, 2022 THROUGH APRIL 30, 2022

PJT Partners LP ("PJT") respectfully represents as follows:

#### I. Background

- 1. On September 15, 2019 (the "Petition Date"), each of the Debtors filed a voluntary petition for relief under chapter 11 of title 11 of the United States Code, 11 U.S.C. §§ 101 et seq., as amended (the "Bankruptcy Code"). The Debtors are operating their businesses and managing their properties as debtors-in-possession pursuant to §§ 1107(a) and 1108 of the Bankruptcy Code.
- 2. On November 5, 2019, the Debtors filed the *Debtors' Application to Employ PJT Partners LP as Investment Banker* Nunc Pro Tunc *to the Petition Date* [Docket No. 430] (the "<u>Retention Application</u>"), pursuant to which the Debtors sought authority to retain and employ

<sup>&</sup>lt;sup>1</sup> The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

PJT as its investment banker pursuant to the terms of an engagement agreement (the "Engagement Agreement") dated May 6, 2019. A copy of the Engagement Agreement was attached to the Retention Application.

- 3. On November 21, 2019, this Court entered the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals* [Docket No. 529] (the "<u>Procedures Order</u>") establishing procedures for interim compensation and reimbursement of out-of-pocket expenses for professionals.
- 4. On January 9, 2020, this Court entered the *Order Approving Debtors' Employment of PJT Partners LP as Investment Banker* Nunc Pro Tunc *to the Petition Date* [Docket No. 728] (the "Retention Order") approving the Retention Application and authorizing the retention and employment of PJT *nunc pro tunc* to the Petition Date, pursuant to the terms of the Engagement Agreement.
- 5. PJT submits this eighth interim fee application (the "<u>Eighth Interim Fee Application</u>") requesting the allowance of Monthly Fees (as defined herein) earned for investment banking services rendered by it as investment banker to the Debtors, and the reimbursement of out-of-pocket expenses incurred during the period of February 1, 2022 through April 30, 2022 (the "<u>Eighth Interim Period</u>").
- 6. Investment banking services and out-of-pocket expenses for which compensation and reimbursement are sought were rendered and expended on behalf of the Debtors pursuant to chapter 11 of the Bankruptcy Code.

### II. The PJT Engagement

- 7. Pursuant to the Engagement Agreement, PJT was retained to provide the following services to the Debtors:<sup>2</sup>
  - (a) assist in the evaluation of the Debtors' businesses and prospects, opportunities and financial condition;
  - (b) assist in the evaluation of the Debtors' long-term business plan and related financial projections;
  - (c) assist in the development of presentations to the Debtors' Board of Directors, various creditors and other third parties;
  - (d) analyze the Debtors' financial liquidity;
  - (e) analyze various restructuring scenarios and the potential impact of these scenarios on the recoveries of those stakeholders impacted by the Restructuring;
  - (f) participate in negotiations among the Debtors and their creditors, and other interested parties;
  - (g) value securities offered by the Debtors in connection with a Restructuring;
  - (h) assist in arranging financing for the Debtors, as requested;
  - (i) provide expert witness testimony concerning any of the subjects encompassed by the other investment banking services;
  - (j) assist the Debtors in preparing marketing materials in conjunction with a possible Transaction:
  - (k) assist the Debtors in identifying potential buyers or parties in interest to a Transaction and assist in the due diligence process;
  - (l) assist and advise the Debtors concerning the terms, conditions and impact of any proposed Transaction; and
  - (m) provide such other advisory services as are customarily provided in connection with the analysis and negotiation of a transaction similar to a potential Restructuring and/or Transaction, as requested and mutually agreed.

<sup>&</sup>lt;sup>2</sup> Capitalized terms used but not defined herein shall have the meanings provided thereto in the Engagement Agreement.

- 8. Pursuant to the Engagement Agreement, as approved by the Retention Order, the Debtors agreed to pay PJT as follows in consideration for the services rendered:<sup>3</sup>
  - (a) Monthly Fee. The Debtors shall pay PJT a monthly advisory fee (the "Monthly Fee") of \$225,000 per month. Fifty percent (50%) of all Monthly Fees paid to PJT between the period beginning on April 1, 2019 and ending on March 31, 2021 shall be credited against any Restructuring Fee (as described below).
  - (b) <u>Capital Raising Fee</u>. The Debtors shall pay PJT a capital raising fee (the "<u>Capital Raising Fee</u>") for any financing arranged by PJT, earned and payable in accordance with the Engagement Agreement as modified by the Retention Order. The Capital Raising Fee will be calculated as:
    - Senior Debt. 1.0% of the total issuance size of the senior debt financing;
    - Junior Debt. 3.0 of the total issuance size of the junior debt financing;
    - Equity Financing. 5.0% of the issuance amount for equity financing.
  - (c) <u>Restructuring Fee</u>. The Debtors shall pay PJT a restructuring fee equal to \$15,000,000.00 (the "<u>Restructuring Fee</u>") earned and payable upon the consummation of a Restructuring.
  - (d) <u>Transaction Fee</u>. Upon consummation of a Transaction, the Debtors shall pay PJT a transaction fee of 2.0% of the Transaction Value (the "<u>Transaction Fee</u>"); provided that, the Transaction Fee in respect of a Transaction involving (a) a sale of the products Lemborexant or Adhansia shall, in each case, not be less than \$1,500,000 (\$3,000,000 for a sale involving both products) or (b) a sale of the Debtors' over-the-counter drug business shall not be less than \$3,000,000 (each such fee, a "<u>Minimum Fee</u>").
    - Notwithstanding any provision on the Engagement Agreement to the contrary, the maximum aggregate amount payable to PJT in respect of all Restructuring Fees, Transaction Fees, and Capital Raising Fees, after giving effect to any crediting of other fees earned under the Engagement Letter, shall be \$23,500,000. For the avoidance of doubt, the foregoing cap on fees shall not include or affect any Monthly Fees due under the Engagement Agreement, the Debtors' obligations to pay PJT Partners' out-of-pocket expenses or the Debtors' obligations under and in respect of the Indemnification Agreement.
  - (e) Expense Reimbursement. In addition to the fees described above, the Debtors agree to reimburse PJT for all reasonable and documented out-of-pocket expenses incurred during this engagement, including, but not limited to, travel and lodging, direct identifiable data processing, document production, publishing services and communication charges, courier services, working meals, reasonable and documented fees and expenses of PJT's

4

<sup>&</sup>lt;sup>3</sup> This description of PJT's compensation structure is for summary and illustrative purposes only. The terms of the Engagement Agreement and the Retention Order shall apply to any such compensation awarded to PJT.

counsel (without the requirement that the retention of such counsel be approved by the Court) and other necessary expenditures, payable upon rendition of invoices setting forth in reasonable detail the nature and amount of such expenses.

#### III. Services Provided by PJT during the Eighth Interim Period

- 9. PJT has rendered professional services to the Debtors as requested and in furtherance of the interests of the Debtors' estates. The variety and complexity of the issues in these chapter 11 cases and the need to act or respond to such issues on an expedited basis have required the expenditure of substantial time by PJT personnel. PJT respectfully submits that the professional services that it rendered on behalf of the Debtors were necessary and appropriate, and have directly contributed to the effective administration of these chapter 11 cases. The following summary of services rendered during the Eighth Interim Period is not intended to be an exhaustive description of the work performed but, rather, is merely an attempt to highlight certain of those areas in which PJT rendered services to the Debtors:
  - (a) assisting Debtors' management with various business and financial analyses;
  - (b) assisting Debtors' management in the evaluation of the Debtors' businesses prospects and opportunities;
  - (c) assisting in the development of financial data and presentations to the Debtors' Board of Directors;
  - (d) attending meetings of the Debtors' Board of Directors;
  - (e) presenting materials to advisors of various creditors;
  - (f) assisting the Debtors in responding to diligence requests from various creditors or other third parties;
  - (g) attending meetings and negotiations with counsel and financial advisors to various creditors;
  - (h) providing support to counsel with regard to various matters;
  - (i) attending various court hearings; and
  - (j) coordinating and participating in update calls with management and counsel regarding various case matters.

#### IV. The PJT Team

10. The investment banking services set forth above were performed primarily by: Jamie O'Connell, Partner; Joe Turner, Managing Director; Rafael Schnitzler, Managing Director; Tom Melvin, Vice President; Jovana Arsic, Vice President; Lukas Schwarzmann, Analyst; and other PJT professionals as needed. Details of the background and experience of the professionals currently employed at PJT are provided in <u>Appendix A</u>.

#### V. PJT's Request for Allowance of Compensation and Reimbursement of Expenses

- 11. For the Eighth Interim Period, PJT seeks (a) allowance of Monthly Fees in the amount of \$675,000.00, and (b) the reimbursement of out-of-pocket expenses incurred in the amount of \$397.71. Although every effort has been made to include all expenses incurred during the Eighth Interim Period, some expenses might not be included in this Eighth Interim Fee Application due to delays caused in connection with the accounting and processing of such expenses. Accordingly, PJT reserves the right to make further application to this Court for allowance of such expenses incurred during the Eighth Interim Period but not included herein.
- 12. Invoices detailing the compensation earned, and the out-of-pocket expenses incurred during the Eighth Interim Period are attached hereto as <u>Appendix B</u>. A summary of all fees earned and out-of-pocket expenses incurred during the Eighth Interim Period is outlined below:

Advisory Periods	Advisory Fees	Out-of-Pocket Expenses	Amount Due
02/01/22 - 02/28/22	\$225,000.00	\$264.78	\$225,264.78
03/01/22 - 03/31/22	225,000.00	-	225,000.00
04/01/22 - 04/30/22	225,000.00	132.93	225,132.93
Total	\$675,000.00	\$397.71	\$675,397.71

13. PJT respectfully submits that the compensation requested for the services rendered by PJT to the Debtors during the Eighth Interim Period is fully justified and reasonable based upon (a) the complexity of the issues presented, (b) the skill necessary to perform the financial advisory services properly, (c) the preclusion of other employment, (d) the customary fees

charged to clients in non-bankruptcy situations for similar services rendered, (e) time constraints required by the exigencies of the case, and (f) the experience, reputation and ability of the professionals rendering services.

14. PJT respectfully submits that the services it has rendered to the Debtors have been necessary and in the best interests of the Debtors and the Debtors' estates. PJT respectfully submits that under the criteria normally examined in chapter 11 reorganization cases, the compensation requested by PJT is reasonable in light of the work performed by PJT during these chapter 11 cases.

15. The amount of fees sought in this Eighth Interim Fee Application and PJT's compensation practices are consistent with market practices both in and out of a bankruptcy context. PJT has never billed its clients based on the number of hours expended by its professionals. Accordingly, PJT does not have hourly rates for its professionals and PJT's professionals generally do not maintain detailed time records of the work performed for its clients. PJT has, however, maintained contemporaneous time records in one-half hour increments. Time records with respect to the 542.5 hours expended by PJT professionals in providing investment banking services to the Debtors during the Eighth Interim Period are provided in Appendix C.

16. A summary of hours expended by PJT professionals during the Eighth Interim Period is provided below:

**Hours Expended By Professional** 

Professional	February 2022	March 2022	April 2022	Total
Jamie O'Connell	13.5	6.0	7.5	27.0
Joe Turner	31.5	19.5	-	51.0
Rafael Schnitzler	49.0	8.0	14.5	71.5
Tom Melvin	66.5	60.5	108.5	235.5
Jovana Arsic	38.5	1.0	-	39.5
Lukas Schwarzmann	39.0	35.5	43.5	118.0
Total	238.0	130.5	174.0	542.5

- 17. Out-of-pocket expenses incurred by PJT are charged to a client if out-of-pocket expenses are incurred for the client or are otherwise necessary in connection with services rendered for such particular client. PJT does not factor general overhead expenses into any disbursements charged to its clients in connection with chapter 11 cases. PJT has followed its general internal policies with respect to out-of-pocket expenses billed as set forth below, with any exceptions specifically explained.
  - (a) All cross-country airfare charges are based upon coach class rates.
  - (b) With respect to local travel, PJT's general policy enables employees to travel by taxi or, in certain circumstances private car service, to and from meetings while rendering services to a client on a client related matter, for which the client is charged. Further, and primarily for safety reasons, employees are permitted to charge to a client the cost of transportation home if an employee is required to work past 9:00 p.m. on weekdays on client specific matters.
  - (c) PJT's general policy permits its professionals to charge dinner meals to a client after working 3 hours beyond their regularly scheduled workday if an employee is required to provide services to the client during such dinnertime, and to charge meals on the weekend if an employee is required to provide services to a client on the weekend and spends at least 4 hours working.
  - (d) The External Research category of expenses includes charges from outside computer/electronic service companies that supply, for a fee, research and/or financial documents to PJT. The services provided by these companies primarily consist of the retrieval of financial documents from regulatory agencies and/or the retrieval of research that would not otherwise be available to PJT. The Internal Research category of expenses are the charges for time spent by PJT research staff in operating the computer/electronic terminals related to these computer/electronic service companies.

- (e) The Publishing Services category of expenses includes charges for the production of textbased publications such as research reports and presentations, and printing and binding services.
- 18. All services for which PJT requests compensation were performed for and on behalf of the Debtors and not on behalf of any other person or stakeholder.
- 19. No agreement or understanding exists between PJT and any other entity for the sharing of compensation received or to be received for services rendered in or in connection with these proceedings.

#### VI. Requested Relief

#### **WHEREFORE**, PJT requests that the Court:

- (a) allow and grant interim approval of (i) Monthly Fees earned by PJT in the amount of \$675.000.00, and (ii) the reimbursement of out-of-pocket expenses incurred by PJT in the amount of \$397.71 for the Eighth Interim Period;
- (b) authorize and direct Debtors to pay PJT's allowed and unpaid fees and out-of-pocket expenses earned or incurred during the Eighth Interim Period as follows:

Monthly Fees \$675,000.00 397.71 **Out-Of-Pocket Expenses Amount Due PJT** \$675,397.71

and

(c) grant such other and further relief as the Court deems just and proper.

Dated: May 16, 2022 Investment Banker to the Debtors

By: /s/ John James O'Connell III

PJT Partners LP

John James O'Connell III Partner 280 Park Avenue New York, NY 10017 (212) 364-7800

## UNITED STATES BANRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK

In re:

PURDUE PHARMA L.P., et al.,

Debtors.1

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

# CERTIFICATION UNDER GUIDELINES FOR FEES AND OUT-OF-POCKET EXPENSES FOR PROFESSIONALS IN RESPECT OF EIGHTH INTERIM APPLICATION OF PJT PARTNERS LP FOR ALLOWANCE OF COMPENSATION AND REIMBURSEMENT OF OUT-OF POCKET EXPENSES

John James O'Connell III, being duly sworn, deposes and says:

- 1. I am a partner with the applicant firm, PJT Partners LP ("PJT").
- 2. In accordance with the guidelines established by the Amended Guidelines for Fees and Disbursements for Professionals in Southern District of New York Bankruptcy Cases, adopted by the Court on January 29, 2013 (updated as of June 17, 2013) (the "Local Guidelines"), the Office of the United States Trustee (the "UST Guidelines") and the Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses of Professionals [Docket No. 175] (the "Procedures Order," and together with the UST Guidelines and the Local Guidelines, the "Guidelines"), this certification is made with respect to PJT's eighth interim application, dated May 16, 2022 (the "Eighth Interim Fee

<sup>1</sup> 

<sup>&</sup>lt;sup>1</sup> The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 13 of 50

Application"), for allowance of compensation earned and reimbursement of out-of-pocket

expenses incurred for the period of February 1, 2022 through April 30, 2022.

3. In respect of section B.1 of the Local Guidelines, I certify that:

a. I have read the Eighth Interim Fee Application;

b. To the best of my knowledge, information, and belief formed after reasonable inquiry, the fees and disbursements sought fall within the Local Guidelines and

the UST Guidelines;

c. The fees and out-of-pocket expenses sought are customarily charged by PJT and

generally accepted by PJT's clients; and

d. In providing a reimbursable service, PJT does not make a profit on that service,

whether the service is performed by PJT in-house or through a third party.

4. With respect to Section B.2 of the Local Guidelines, I certify that, to the best of my

knowledge, information and belief, the Debtors and the United States Trustee for the Southern

District of New York (the "U.S. Trustee") have been provided with a statement of the fees

and out-of-pocket expenses incurred for each month subject to the Eighth Interim Fee

Application, although such statements may not have always been provided within the exact

timetables set forth in the Procedures Order.

5. With respect to section B.3 of the Local Guidelines, I certify that the Debtors and the

U.S. Trustee are each being provided with a copy of PJT's Eighth Interim Fee Application.

By: /s/ John James O'Connell III

John James O'Connell III

Partner

2

## **APPENDIX A**

#### **Biographies of PJT Professionals**

- Jamie O'Connell. Mr. O'Connell is a Partner in the Restructuring and Special Situations Group (RSSG), having joined the predecessor group of RSSG at Blackstone in 2004. Mr. O'Connell was a Senior Managing Director at Blackstone at the time of the group's spinoff to PJT in 2015. His chapter 11 experience includes Aegean Marine Petroleum Network Babcock & Wilcox, Central European Distribution Corp. (CEDC), Dow Corning, Excel Maritime Carriers, Genco Shipping & Trading, Mrs. Fields Famous Brands, Nautilus Holdings, New World Pasta, Overseas Shipholding Group (OSG), Simmons Bedding Company, Solutia, Specialty Products Holding Corp., Stearns Holdings, Targus, Toisa, Ultrapetrol, W. R. Grace & Co., and Winn-Dixie Stores. Before joining Blackstone, Mr. O'Connell worked at Dolphin Equity Partners LP and in the Corporate Recovery Services Group of Arthur Andersen LLP. He graduated magna cum laude from Notre Dame and received an MBA with honors from the Wharton School.
- Rafael Schnitzler. Mr. Schnitzler is a Managing Director in the Strategic Advisory Group. Mr. Schnitzler joined PJT Partners in 2015 and has advised on a variety of mergers and acquisitions. Prior to joining PJT Partners, Mr. Schnitzler worked at Deutsche Bank. Mr. Schnitzler graduated from UC Davis with a BA in economics and received an MBA from the University of Virginia.
- Tom Melvin. Mr. Melvin is a Vice President in the Restructuring & Special Situations Group and has advised on a number of in and out-of-court restructuring transactions including PaperWorks Industries, Expanse Energy Solutions, Aspect Software and Legacy Reserves. Before joining PJT Partners in 2017, Tom worked as an investment banking analyst at an industry focused boutique in New York City, executing capital raising and merger and acquisition transactions in the healthcare and chemical industries. Prior to that Mr. Melvin was an associate at Deloitte. Tom graduated with High Honors from the University of Illinois where he obtained both a Bachelor's and Master's degree in Accountancy. He also received an MBA from Northwestern University's Kellogg School of Management where he completed majors in Finance and Health Enterprise Management. He is also a CPA.
- **Jovana Arsic.** Ms Arsic is an Vice President in the Restructuring & Special Situations Group. Ms. Arsic has previously been based in PJT Partners' London office, where she advised on variety of in and out-of-court restructuring transactions, including advising Extraordinary Commissioner of Agrokor on negotiations with creditors in €6.0bn quasi-

sovereign restructuring of the Croatian retailer, landlords to Arcadia on the £3.5bn CVA proposal of the leading UK high-street retailer and a group of bank lenders in the \$500m restructuring of DESS, ring-fenced subsidiary of SolstadFalstad, Norwegian offshore operator. Prior to joining PJT Partners in 2017, Jovana worked as an Investment Banking analyst in TMT and Oil & Gas teams of Citigroup London. Ms. Arsic received an MSc. in Finance in 2015 and a BSc. in Finance in 2012, both from Bocconi University in Milan, Italy.

• Lukas Schwarzmann. Mr. Schwarzmann is an Analyst in the Restructuring and Special Situations Group at PJT Partners. Mr. Schwarzmann graduated from Harvard University with a BA in Applied Mathematics.

## **APPENDIX B**

## 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 18 of 50

259.08

5.70

## PJT Partners

PJ7 May 4, 2022

Terrence Ronan Purdue Pharma LP 201 Tresser Boulevard Stamford, CT 06901-3431

Monthly Fee for the period of February 1, 2022 through February 28, 2022:

\$ 225,000.00

Out-of-pocket expenses processed through March 22, 2022:<sup>(1)</sup>

Ground Transportation \$
Research

264.78

225,264.78

**Total Amount Due** 

\$

Invoice No. 10020596

PJT Partners LP

Finance Department - 17th Floor 280 Park Avenue New York, NY 10017 212 364-7800

PJTUSInvoicing@pjtpartners.com

<sup>(1)</sup> Expenses incurred, but not yet processed due to timing differences will be billed at a later date.

### Purdue Pharma LP Summary of Expenses

Ground Transportation
Research - Online Database
<b>Total Expenses</b>

G	L Detail	Total Expenses		
]	Mar-22			
\$	259.08	\$	259.08	
	5.70		5.70	
\$	264.78	\$	264.78	
Groun	d Transportation	\$	259.08	
Research			5.70	
Total l	Expenses	\$	264.78	

## 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 20 of 50

Purdue Pharma LP Detail of Expenses Processed Through March 22, 2022 Invoice No. 10020596

Ground Transportation			
Turner (taxi to client offices in Stamford, CT from home)	02/25/22	142.15	
Turner (taxi home from client offices in Stamford, CT)	02/25/22	116.93	
	Subtotal - Ground Transportation		\$ 259.08
Research - Online Database			
de Almeida (retrieved documents from Court docket via PACER)	08/02/21	4.60	
de Almeida (retrieved documents from Court docket via PACER)	11/04/21	1.10	
	Subtotal - Research - Online Database		 5.70
	Total Expenses		\$ 264.78

## 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 21 of 50

## PJT Partners



Terrence Ronan Purdue Pharma LP 201 Tresser Boulevard Stamford, CT 06901-3431

Monthly Fee for the period of March 1, 2022 through March 31, 2022:

\$ 225,000.00

**Total Amount Due**<sup>(1)</sup>

\$ 225,000.00

**Invoice No. 10020907** 

PJT Partners LP

Finance Department - 17th Floor 280 Park Avenue New York, NY 10017 212 364-7800 PJTUSInvoicing@pjtpartners.com

<sup>(1)</sup> Expenses incurred, but not yet processed due to timing differences will be billed at a later date.

## 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 22 of 50

## PJT Partners

PJ7 May 4, 2022

225,000.00

Terrence Ronan Purdue Pharma LP 201 Tresser Boulevard Stamford, CT 06901-3431

	Monthly Fee for the	period of April 1	, 2022 through April 30, 2022:	\$
--	---------------------	-------------------	--------------------------------	----

Out-of-pocket expenses processed through April 26, 2022:<sup>(1)</sup>

Ground Transportation	\$ 116.93	
Communications	16.00	132.93

Total Amount Due \$ 225,132.93

Invoice No. 10020965

**PJT Partners LP** 

Finance Department - 17th Floor 280 Park Avenue New York, NY 10017 212 364-7800

PJTUSInvoicing@pjtpartners.com

<sup>(1)</sup> Expenses incurred, but not yet processed due to timing differences will be billed at a later date.

### Purdue Pharma LP Summary of Expenses

	G	GL Detail		Total
	Apr-22		Expenses	
Ground Transportation	\$	116.93	\$	116.93
Communications		16.00		16.00
<b>Total Expenses</b>	\$	132.93	\$	132.93
		d Transportation unications	\$	116.93 16.00
	Total I	Expenses	\$	132.93

## 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 24 of 50

Purdue Pharma LP Detail of Expenses Processed Through April 26, 2022 Invoice No. 10020965

Ground Transportation			
Turner (taxi home from client offices in Stamford, CT)	02/25/22	116.93	
	<b>Subtotal - Ground Transportation</b>	'	\$ 116.93
Communications			
Melvin (wi-fi access while traveling)	12/27/21	8.00	
Melvin (wi-fi access while traveling)	01/23/22	8.00	
	<b>Subtotal - Communications</b>		 16.00
	Total Expenses		\$ 132.93

## **APPENDIX C**

# 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 26 of 50 PJT PARTNERS LP

## PJT PARTNERS LP SUMMARY OF HOURS FOR THE PERIOD OF

## FEBRUARY 1, 2022 THROUGH FEBRUARY 28, 2022

Professional	Title	Hours
Jamie O'Connell	Partner	13.5
Joe Turner	Managing Director	31.5
Rafael Schnitzler	Managing Director	49.0
Tom Melvin	Vice President	66.5
Jovana Arsic	Vice President	38.5
Lukas Schwarzmann	Analyst	39.0
	Total	238.0

### 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document

## Pg 27 of 50 PJT PARTNERS LP

Professional	Date	Hours	Explanation
Jamie O'Connell	02/01/22	1.0	Call with management and advisors regarding various matters
Jamie O'Connell	02/07/22	0.5	Call regarding financial matters
Jamie O'Connell	02/08/22	0.5	Call regarding financial matters
Jamie O'Connell	02/08/22	0.5	Special Committee
Jamie O'Connell	02/09/22	1.0	Calls regarding financial matters
Jamie O'Connell	02/10/22	0.5	Weekly update call with management and advisors
Jamie O'Connell	02/17/22	0.5	Calls regarding financial matters
Jamie O'Connell	02/17/22	0.5	Call with R. Schnitzler regarding financial analysis
Jamie O'Connell	02/21/22	0.5	Call with J. Turner regarding various matters
Jamie O'Connell	02/22/22	0.5	Special Committee
Jamie O'Connell	02/23/22	1.0	Calls regarding financial matters
Jamie O'Connell	02/24/22	1.0	Weekly update call with management and advisors
Jamie O'Connell	02/25/22	4.5	Board Meeting
Jamie O'Connell	02/27/22	0.5	Review and comment on draft fee statement
Jamie O'Connell	02/28/22	0.5	Call regarding financial matters
		13.5	

# 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 28 of 50 PJT PARTNERS LP

Professional	Date	Hours	Explanation
Joe Turner	02/01/22	1.0	Call with management and advisors regarding various matters
Joe Turner	02/07/22	0.5	Call regarding financial matters
Joe Turner	02/07/22	2.0	Review and drafting of various financial analyses
Joe Turner	02/08/22	0.5	Call regarding financial matters
Joe Turner	02/08/22	0.5	Special Committee
Joe Turner	02/08/22	2.0	Review and drafting of various financial analyses
Joe Turner	02/09/22	1.0	Calls regarding financial matters
Joe Turner	02/10/22	0.5	Weekly update call with management and advisors
Joe Turner	02/17/22	0.5	Calls regarding financial matters
Joe Turner	02/17/22	2.0	Review of various financial analyses
Joe Turner	02/21/22	0.5	Call with J. O'Connell regarding various matters
Joe Turner	02/22/22	2.0	Review and drafting of various financial analyses
Joe Turner	02/23/22	1.0	Calls regarding financial matters
Joe Turner	02/23/22	1.0	Call with creditor advisors regarding various matters
Joe Turner	02/23/22	2.5	Review and drafting of various financial analyses
Joe Turner	02/24/22	3.0	Preparation of various materials for Board Meeting
Joe Turner	02/24/22	1.0	Weekly update call with management and advisors
Joe Turner	02/24/22	1.0	Review and drafting of various financial analyses
Joe Turner	02/24/22	2.0	Preparation of speaking points for Board Meeting
Joe Turner	02/24/22	0.5	Call with creditor advisors regarding financial item
Joe Turner	02/25/22	5.5	Board Meeting
Joe Turner	02/27/22	0.5	Review and comment on draft fee statement
Joe Turner	02/28/22	0.5	Call regarding financial matters
		31.5	

# 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 29 of 50 PJT PARTNERS LP

Professional	Date	Hours	Explanation
Rafael Schnitzler	02/01/22	2.0	Research and preparation for Board meeting
Rafael Schnitzler	02/03/22	2.5	Research and preparation for Board meeting
Rafael Schnitzler	02/04/22	1.0	Research and preparation for Board meeting
Rafael Schnitzler	02/09/22	6.0	Review and drafting of various presentations
Rafael Schnitzler	02/10/22	0.5	Weekly update call with management and advisors
Rafael Schnitzler	02/10/22	3.0	Review and drafting of various presentations
Rafael Schnitzler	02/11/22	1.0	Review and drafting of various presentations
Rafael Schnitzler	02/12/22	4.5	Research in preparation for Board meeting
Rafael Schnitzler	02/15/22	3.0	Review and drafting of various presentations
Rafael Schnitzler	02/16/22	2.5	Review and drafting of various presentations
Rafael Schnitzler	02/18/22	0.5	Calls regarding financial matters
Rafael Schnitzler	02/20/22	1.5	Review and drafting of various presentations
Rafael Schnitzler	02/21/22	0.5	Call with J. O'Connell regarding various matters
Rafael Schnitzler	02/22/22	2.0	Review and drafting of various financial analyses
Rafael Schnitzler	02/23/22	1.0	Review and drafting of various presentations
Rafael Schnitzler	02/23/22	2.5	Review and drafting of various financial analyses
Rafael Schnitzler	02/24/22	3.5	Review and drafting of various presentations
Rafael Schnitzler	02/24/22	3.0	Preparation of various materials for Board Meeting
Rafael Schnitzler	02/24/22	1.0	Weekly update call with management and advisors
Rafael Schnitzler	02/24/22	2.0	Preparation of speaking points for Board Meeting
Rafael Schnitzler	02/25/22	5.5	Board Meeting
		49.0	

# 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 30 of 50 PJT PARTNERS LP

Date	Hours	Explanation
	·	
		Review and prepare responses to creditor advisor diligence requests
		Respond to requests from DPW
		E-mail correspondence with Company management and DPW regarding various requests
		Review and prepare responses to creditor advisor diligence requests
		E-mail correspondence with Company management and AlixPartners regarding various matters
		Review questions from AlixPartners
02/03/22	1.0	Weekly call with Company management and debtor advisors
02/03/22	0.5	Call with internal team to discuss requests from Board
02/03/22	1.5	Aggregate materials and review analyses related to Board requests
02/03/22	1.0	Review and prepare responses to creditor advisor diligence requests
02/03/22	0.5	Review AlixPartners draft presentation
02/03/22	1.0	Review Company analysis related to business development opportunity
02/04/22	1.5	Aggregate materials and review analyses related to Board requests
02/04/22	2.0	Review and prepare responses to creditor advisor diligence requests
02/06/22	1.0	Respond to requests from DPW
02/07/22	1.0	Aggregate materials and review analyses related to Board requests
02/07/22	0.5	Call with internal team to discuss responses to requests from Board
02/08/22	1.0	Attended telephonic Special Committee meeting
02/08/22	1.0	Call with Company management, DPW and AlixPartners to discuss business development
02/08/22	2.0	Aggregate materials and review analyses related to Board requests
02/08/22	1.0	Review Company analysis related to business development opportunity
02/09/22	0.5	Call with Company management to discuss financial analysis
02/09/22	1.0	Review materials from Company management related to requests from Board
02/09/22	1.5	Aggregate materials and review analyses related to Board requests
02/10/22	1.0	Weekly call with Company management and debtor advisors
02/10/22	1.0	Review materials from Company management related to business development opportunities
02/11/22	0.5	Call with Company management to discuss business development and financial analyses
02/11/22	2.0	Review materials requested by Company management related to business development opportunity
02/11/22	1.0	Review analyses related to Board requests
02/11/22	1.0	Review analyses from Company management related to requests from Board
		Review materials requested by Company management related to business development opportunity
02/13/22		Review materials requested by Company management related to business development opportunity
02/14/22	1.0	Review analyses from Company management related to requests from Board
	02/01/22 02/01/22 02/01/22 02/02/22 02/02/22 02/02/22 02/03/22 02/03/22 02/03/22 02/03/22 02/03/22 02/03/22 02/03/22 02/03/22 02/04/22 02/04/22 02/04/22 02/06/22 02/07/22 02/07/22 02/08/22 02/08/22 02/08/22 02/08/22 02/08/22 02/08/22 02/08/22 02/09/22 02/09/22 02/09/22 02/10/22 02/11/22 02/11/22 02/11/22 02/11/22 02/11/22 02/12/22 02/13/22	02/01/22       2.0         02/01/22       1.0         02/02/22       1.0         02/02/22       1.0         02/02/22       1.0         02/02/22       0.5         02/03/22       1.0         02/03/22       1.5         02/03/22       1.0         02/03/22       1.0         02/03/22       1.0         02/03/22       1.0         02/03/22       1.0         02/03/22       1.0         02/03/22       1.0         02/04/22       2.0         02/04/22       1.0         02/07/22       0.5         02/07/22       0.5         02/08/22       1.0         02/08/22       1.0         02/08/22       1.0         02/09/22       0.5         02/09/22       1.5         02/09/22       1.0         02/10/22       1.0         02/10/22       1.0         02/10/22       1.0         02/11/22       2.0         02/11/22       1.0         02/11/22       1.0         02/11/22       1.0         02/11/22       1.0

# 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 31 of 50 PJT PARTNERS LP

Professional	Date	Hours	Explanation
TT1	02/14/22	1.5	
Thomas Melvin	02/14/22	1.5	Review materials from Company management related to business development opportunities
Thomas Melvin	02/15/22	1.0	Call with Company management, DPW and AlixPartners to discuss business development
Thomas Melvin	02/15/22	1.0	Review analyses related to Board requests
Thomas Melvin	02/16/22	0.5	Call with Company management to discuss business development
Thomas Melvin	02/16/22	1.5	Review analyses related to Board requests
Thomas Melvin	02/17/22	1.0	Weekly call with Company management and debtor advisors
Thomas Melvin	02/17/22	1.0	Dialed into court hearing
Thomas Melvin	02/17/22	1.0	Call with internal team to discuss requests from Board
Thomas Melvin	02/17/22	1.5	Review analyses related to Board requests
Thomas Melvin	02/18/22	2.0	Review analyses related to Board requests
Thomas Melvin	02/20/22	1.5	Review analyses related to Board requests
Thomas Melvin	02/21/22	0.5	Review materials from Company management related to business development opportunities
Thomas Melvin	02/21/22	0.5	Review materials from Company management related to public health initiatives
Thomas Melvin	02/21/22	0.5	Review agenda for upcoming board meeting
Thomas Melvin	02/22/22	0.5	Attended telephonic Special Committee meeting
Thomas Melvin	02/22/22	1.0	Review and prepare responses to creditor advisor diligence requests
Thomas Melvin	02/22/22	1.0	Review AlixPartners draft presentation
Thomas Melvin	02/23/22	1.5	Review draft Board materials
Thomas Melvin	02/24/22	1.0	Weekly call with Company management and debtor advisors
Thomas Melvin	02/24/22	0.5	Call with Company management to discuss various legal matters related to requested analyses
Thomas Melvin	02/24/22	0.5	Internal team call to discuss requested analyses
Thomas Melvin	02/24/22	1.0	Call with Company management, DPW and AlixPartners and creditor advisors regarding public health initiatives
Thomas Melvin	02/24/22	1.5	Review draft Board materials
Thomas Melvin	02/24/22	0.5	Review materials from DPW related to upcoming meeting with creditor advisors
Thomas Melvin	02/24/22	1.0	E-mail correspondence with internal team and DPW regarding Board materials
Thomas Melvin	02/25/22	4.0	Attended portion of Board meeting telephonically
Thomas Melvin	02/25/22	1.0	Call with Company management, DPW and AlixPartners and creditor advisors regarding public health initiatives
Thomas Melvin	02/25/22	1.0	Review materials from DPW related to upcoming meeting with creditor advisors
Thomas Melvin	02/28/22	0.5	Call with Company management and AlixPartners to discuss matters related to public health initiatives
Thomas Melvin	02/28/22	0.5	E-mail correspondence with Company management regarding various matters
		66.5	

# 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 32 of 50 PJT PARTNERS LP

Professional	Date	Hours	Explanation
Jovana Arsic	02/01/22	2.0	Listen in to Preliminary Injunction Extension Hearing
Jovana Arsic	02/03/22	1.0	Call with management and advisors regarding various matters
Jovana Arsic	02/03/22	0.5	Internal PJT call on preparation of financial analysis
Jovana Arsic	02/09/22	0.5	Call with Company on preparation of financial analysis
Jovana Arsic	02/10/22	1.0	Call with management and advisors regarding various matters
Jovana Arsic	02/11/22	0.5	Call with Company on preparation of financial analysis
Jovana Arsic	02/14/22	2.0	Preparation and review of financial analysis
Jovana Arsic	02/15/22	3.0	Preparation and review of financial analysis
Jovana Arsic	02/16/22	2.0	Preparation and review of financial analysis
Jovana Arsic	02/16/22	0.5	Call with Company on preparation of financial analysis
Jovana Arsic	02/17/22	1.0	Call with management and advisors regarding various matters
Jovana Arsic	02/17/22	1.0	Listen in to February Omnibus Hearing
Jovana Arsic	02/17/22	3.0	Preparation and review of financial analysis
Jovana Arsic	02/17/22	1.0	Internal PJT call on preparation of financial analysis
Jovana Arsic	02/20/22	3.0	Preparation and review of financial analysis
Jovana Arsic	02/22/22	2.0	Preparation and review of financial analysis
Jovana Arsic	02/23/22	2.0	Calls on financial analysis
Jovana Arsic	02/24/22	1.0	Call with management and advisors regarding various matters
Jovana Arsic	02/24/22	0.5	Call with Davis Polk on financial analysis
Jovana Arsic	02/24/22	5.0	Preparation and review of financial analysis
Jovana Arsic	02/24/22	0.5	Internal PJT call on preparation of financial analysis
Jovana Arsic	02/25/22	5.0	Board Meeting
Jovana Arsic	02/27/22	0.5	Review and comment on draft fee statement
		38.5	

# 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 33 of 50 PJT PARTNERS LP

Professional	Date	Hours	Explanation
	02/02/22	1.0	
Lukas Schwarzmann	02/03/22	1.0	Biweekly call
Lukas Schwarzmann	02/03/22	0.5	Internal catch-up call
Lukas Schwarzmann	02/09/22	0.5	Call with management regarding financial analysis
Lukas Schwarzmann	02/10/22	1.0	Biweekly call
Lukas Schwarzmann	02/10/22	2.0	Financial analysis
Lukas Schwarzmann	02/11/22	1.5	Financial analysis
Lukas Schwarzmann	02/11/22	0.5	Call with management regarding financial analysis
Lukas Schwarzmann	02/15/22	4.0	Financial analysis
Lukas Schwarzmann	02/16/22	0.5	Call with management regarding financial analysis
Lukas Schwarzmann	02/16/22	2.0	Financial analysis
Lukas Schwarzmann	02/17/22	1.0	Biweekly call
Lukas Schwarzmann	02/17/22	0.5	Internal catch-up call
Lukas Schwarzmann	02/17/22	1.0	Financial analysis
Lukas Schwarzmann	02/18/22	4.0	Financial analysis
Lukas Schwarzmann	02/19/22	2.0	Financial analysis
Lukas Schwarzmann	02/20/22	2.0	Financial analysis
Lukas Schwarzmann	02/21/22	1.5	Financial analysis
Lukas Schwarzmann	02/22/22	3.0	Financial analysis
Lukas Schwarzmann	02/23/22	5.0	Financial analysis
Lukas Schwarzmann	02/24/22	1.0	Biweekly call
Lukas Schwarzmann	02/24/22	0.5	Internal catch-up call
Lukas Schwarzmann	02/24/22	4.0	Financial analysis
		39.0	

# 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 34 of 50 PJT PARTNERS LP

# SUMMARY OF HOURS FOR THE PERIOD OF MARCH 31, 2022 THROUGH MARCH 31, 2022

Professional	Title	Hours
Jamie O'Connell	Partner	6.0
Joe Turner	Managing Director	19.5
Rafael Schnitzler	Managing Director	8.0
Tom Melvin	Vice President	60.5
Jovana Arsic	Vice President	1.0
Lukas Schwarzmann	Analyst	35.5
	Total	130.5

# 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 35 of 50 PJT PARTNERS LP

## HOURLY DETAILS FOR THE PERIOD OF **MARCH 1, 2022 THROUGH MARCH 31, 2022**

Date	Hours	Explanation
03/02/22	1.0	Call regarding financial matters with J. Turner
03/03/22	1.0	Weekly update call with management and advisors
03/10/22	1.0	Weekly update call with management and advisors
03/11/22	0.5	Call regarding financial matters
03/23/22	0.5	Review and comment on draft fee application
03/24/22	0.5	Weekly update call with management and advisors
03/24/22	0.5	Call regarding financial matters
03/25/22	0.5	Review and comment on draft fee statement
03/30/22	0.5	Update call with J. Turner
	6.0	
	03/02/22 03/03/22 03/10/22 03/11/22 03/23/22 03/24/22 03/24/22 03/25/22	03/02/22       1.0         03/03/22       1.0         03/10/22       1.0         03/11/22       0.5         03/23/22       0.5         03/24/22       0.5         03/24/22       0.5         03/25/22       0.5         03/30/22       0.5

# 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 36 of 50 PJT PARTNERS LP

## HOURLY DETAILS FOR THE PERIOD OF **MARCH 1, 2022 THROUGH MARCH 31, 2022**

Professional	Date	Hours	Explanation
Joe Turner	03/01/22	1.0	Weekly update call with creditor financial advisors
Joe Turner	03/02/22	1.0	Call regarding financial matters with J. O'Connell
Joe Turner	03/03/22	1.0	Weekly update call with management and advisors
Joe Turner	03/08/22	0.5	Call with T. Melvin to discuss various matters
Joe Turner	03/08/22	1.0	Board Special Committee meeting
Joe Turner	03/10/22	1.0	Weekly update call with management and advisors
Joe Turner	03/11/22	0.5	Call with internal team to discuss various matters
Joe Turner	03/14/22	1.0	Call with Company management and AlixPartners
Joe Turner	03/15/22	1.0	Weekly update call with creditor financial advisors
Joe Turner	03/15/22	1.0	Call with Company management and AlixPartners related to business plan
Joe Turner	03/17/22	1.0	Weekly update call with management and advisors
Joe Turner	03/18/22	1.0	Call with Company management, AlixPartners and DPW to discuss various matters
Joe Turner	03/23/22	1.0	Call with Company management and AlixPartners to discuss public health initiatives
Joe Turner	03/24/22	0.5	Weekly update call with management and advisors
Joe Turner	03/24/22	1.0	Call with Company management and AlixPartners to discuss pipeline products
Joe Turner	03/24/22	0.5	Call with internal team to discuss various matters
Joe Turner	03/28/22	0.5	Call with creditor financial advisors to discuss pipeline products
Joe Turner	03/30/22	0.5	Update call with J. O'Connell
Joe Turner	03/30/22	0.5	Call with internal team to discuss various matters
Joe Turner	03/31/22	4.0	Board meeting
		19.5	-

# 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 37 of 50 PJT PARTNERS LP

Professional	Date	Hours	Explanation
Rafael Schnitzler	03/02/22	1.0	Call with Company management and AlixPartners related to business development
Rafael Schnitzler	03/14/22	1.0	Call with Company management and AlixPartners related to business development
Rafael Schnitzler	03/15/22	1.0	Call with Company management and AlixPartners related to business plan
Rafael Schnitzler	03/16/22	0.5	Call with Company management to discuss financial analysis
Rafael Schnitzler	03/16/22	0.5	Call with Company management to discuss business development
Rafael Schnitzler	03/18/22	1.0	Call with Company management and AlixPartners related to business development
Rafael Schnitzler	03/24/22	0.5	Call with PJT team to discuss various matters
Rafael Schnitzler	03/30/22	0.5	Call with internal team to discuss various matters
Rafael Schnitzler	03/31/22	2.0	Board meeting
		8.0	

# 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 38 of 50 PJT PARTNERS LP

Thomas Melvin   03/01/22   1.0   Weekly update call with creditor financial advisors	Professional	Date	Hours	Explanation
Thomas McIvin         03/02/22         1.0         Call with Company management and AlixPartners regarding business development           Thomas McIvin         03/03/22         1.5         Review analysis from Company           Thomas McIvin         03/03/22         1.5         Review analysis from Company           Thomas McIvin         03/03/22         1.5         Review AlixPartners analysis           Thomas McIvin         03/04/22         1.5         Review Company analysis related to public health initiatives           Thomas McIvin         03/04/22         1.5         Review Company analysis related to business development           Thomas McIvin         03/04/22         0.5         E-mail correspondence with Company management regarding various matters           Thomas McIvin         03/06/22         1.0         Review Company analysis related to business development           Thomas McIvin         03/07/22         0.5         Call with Company management and AlixPartners regarding pipeline products           Thomas McIvin         03/08/22         1.0         Board Special Committee meeting           Thomas McIvin         03/08/22         1.0         Review financial analysis related to Board request           Thomas McIvin         03/09/22         1.0         Call with J. Tumer to discuss various matters           Thomas McIvin         03/10/22 <td>Thomas Melvin</td> <td>03/01/22</td> <td>1.0</td> <td>Weekly update call with creditor financial advisors</td>	Thomas Melvin	03/01/22	1.0	Weekly update call with creditor financial advisors
Thomas Melvin         03/03/22         1.0         Weekly update call with Company management and debtor advisors           Thomas Melvin         03/03/22         1.5         Review analysis from Company           Thomas Melvin         03/03/22         0.5         Review AlixPartners analysis           Thomas Melvin         03/04/22         0.5         Review Company analysis related to public health initiatives           Thomas Melvin         03/04/22         0.5         E-mail correspondence with Company management regarding various matters           Thomas Melvin         03/04/22         0.5         E-mail correspondence with Company management regarding pipeline products           Thomas Melvin         03/08/22         1.0         Review Company analysis related to business development           Thomas Melvin         03/08/22         1.0         Board Special Committee meeting           Thomas Melvin         03/08/22         1.0         Board Special Committee meeting           Thomas Melvin         03/08/22         1.0         Dialed into court hearing           Thomas Melvin         03/09/22         1.0         Dialed into court hearing           Thomas Melvin         03/11/22         1.0         Weekly update call with Company management and debtor advisors           Thomas Melvin         03/11/22         0.5         Call with Comp				
Thomas Melvin         03/03/22         1.5         Review analysis from Company           Thomas Melvin         03/03/22         1.0         E-mail correspondence with Company management and DPW           Thomas Melvin         03/04/22         1.5         Review Company analysis related to public health initiatives           Thomas Melvin         03/04/22         0.5         E-mail correspondence with Company management regarding various matters           Thomas Melvin         03/04/22         0.5         E-mail correspondence with Company management regarding various matters           Thomas Melvin         03/07/22         0.5         Call with Company management and AlixPartners regarding pipeline products           Thomas Melvin         03/08/22         1.0         Board Special Committee meeting           Thomas Melvin         03/08/22         1.0         Board Special Committee meeting           Thomas Melvin         03/08/22         1.0         Review financial analysis related to Board request           Thomas Melvin         03/08/22         1.0         Dialed into court hearing           Thomas Melvin         03/10/22         1.0         Dialed into court hearing           Thomas Melvin         03/10/22         1.0         Dialed into court hearing           Thomas Melvin         03/11/22         0.5         Call with Company mana				
Thomas Melvin03/03/221.0E-mail correspondence with Company management and DPWThomas Melvin03/03/220.5Review AlixPartners analysisThomas Melvin03/04/220.5E-mail correspondence with Company management regarding various mattersThomas Melvin03/04/220.5E-mail correspondence with Company management regarding various mattersThomas Melvin03/06/221.0Review Company analysis related to business developmentThomas Melvin03/08/221.0Board Special Committee meetingThomas Melvin03/08/221.0Review financial analysis related to Board requestThomas Melvin03/08/221.0Review financial analysis related to Board requestThomas Melvin03/08/221.0Dialed into court hearingThomas Melvin03/10/221.0Weekly update call with Company management and debtor advisorsThomas Melvin03/10/221.0Dialed into court hearingThomas Melvin03/11/221.0Dialed into court hearingThomas Melvin03/11/221.0Call with Company management and AlixPartners regarding public health initiative productsThomas Melvin03/11/220.5Call with internal team to discuss various mattersThomas Melvin03/11/220.5Review financial analysis from Company managementThomas Melvin03/11/220.5Review financial analysis from Company management regarding various mattersThomas Melvin03/11/220.5Call with AlixPartners to discuss various matters <td< td=""><td></td><td></td><td></td><td></td></td<>				
Thomas McIvin03/03/220.5Review Alix Partners analysisThomas McIvin03/04/221.5Review Company analysis related to public health initiativesThomas McIvin03/06/221.0Review Company analysis related to business developmentThomas McIvin03/06/221.0Review Company analysis related to business developmentThomas McIvin03/08/220.5Call with Company management and AlixPartners regarding pipeline productsThomas McIvin03/08/221.0Board Special Committee meetingThomas McIvin03/08/221.0Review financial analysis related to Board requestThomas McIvin03/08/220.5Call with J. Turner to discuss various mattersThomas McIvin03/08/221.0Dialed into court hearingThomas McIvin03/10/221.0Weekly update call with Company management and debtor advisorsThomas McIvin03/10/221.0Dialed into court hearingThomas McIvin03/11/220.5Call with Company management and AlixPartners regarding public health initiative productsThomas McIvin03/11/220.5Call with internal team to discuss various mattersThomas McIvin03/11/220.5Review financial analysis from Company managementThomas McIvin03/11/220.5Review financial analysis from Company management regarding various mattersThomas McIvin03/11/220.5Review financial analysis from Company management regarding various mattersThomas McIvin03/13/220.5Review financial analysis				
Thomas Melvin03/04/221.5Review Company analysis related to public health initiativesThomas Melvin03/04/220.5E-mail correspondence with Company management regarding various mattersThomas Melvin03/07/220.5Call with Company management and AlixPartners regarding pipeline productsThomas Melvin03/08/221.0Board Special Committee meetingThomas Melvin03/08/221.0Review financial analysis related to Board requestThomas Melvin03/08/220.5Call with J. Turner to discuss various mattersThomas Melvin03/09/221.0Dialed into court hearingThomas Melvin03/10/221.0Dialed into court hearingThomas Melvin03/10/221.0Dialed into court hearingThomas Melvin03/10/221.0Call with Company management and AlixPartners regarding public health initiative productsThomas Melvin03/11/221.0Call with Company management and AlixPartners regarding public health initiative productsThomas Melvin03/11/220.5Call with Internal team to discuss various mattersThomas Melvin03/11/220.5Review financial analysis from Company managementThomas Melvin03/11/220.5Review AlixPartners analysisThomas Melvin03/11/220.5E-mail correspondence with AlixPartners and Company management regarding various mattersThomas Melvin03/13/220.5Review analysis from Company management and AlixPartnersThomas Melvin03/14/220.5Review analysis from				
Thomas Melvin03/04/220.5E-mail correspondence with Company management regarding various mattersThomas Melvin03/06/221.0Review Company analysis related to business developmentThomas Melvin03/08/221.0Board Special Committee meetingThomas Melvin03/08/221.0Review financial analysis related to Board requestThomas Melvin03/08/221.0Review financial analysis related to Board requestThomas Melvin03/09/221.0Dialed into court hearingThomas Melvin03/10/221.0Weekly update call with Company management and debtor advisorsThomas Melvin03/10/221.0Dialed into court hearingThomas Melvin03/11/221.0Dialed into court hearingThomas Melvin03/11/221.0Dialed into court hearingThomas Melvin03/11/221.0Call with Company management and debtor advisorsThomas Melvin03/11/220.5Call with Company management and AlixPartners regarding public health initiative productsThomas Melvin03/11/220.5Review financial analysis from Company managementThomas Melvin03/11/220.5Review AlixPartners analysisThomas Melvin03/11/220.5Call with AlixPartners to discuss various mattersThomas Melvin03/13/221.5Review analysis from Company management and AlixPartnersThomas Melvin03/14/220.5Review analysis from Company management and AlixPartners regarding business developmentThomas Melvin03/14/22 </td <td></td> <td></td> <td></td> <td>•</td>				•
Thomas Melvin03/06/221.0Review Company analysis related to business developmentThomas Melvin03/07/220.5Call with Company management and AlixPartners regarding pipeline productsThomas Melvin03/08/221.0Review financial analysis related to Board requestThomas Melvin03/08/220.5Call with J. Turner to discuss various mattersThomas Melvin03/09/221.0Dialed into court hearingThomas Melvin03/10/221.0Weekly update call with Company management and debtor advisorsThomas Melvin03/10/221.0Dialed into court hearingThomas Melvin03/11/221.0Call with Company management and AlixPartners regarding public health initiative productsThomas Melvin03/11/220.5Call with Internal team to discuss various mattersThomas Melvin03/11/220.5Review financial analysis from Company managementThomas Melvin03/11/220.5Review AlixPartners analysisThomas Melvin03/11/220.5E-mail correspondence with AlixPartners and Company management regarding various mattersThomas Melvin03/11/220.5Call with AlixPartners to discuss various mattersThomas Melvin03/13/221.5Review analysis from Company management and AlixPartnersThomas Melvin03/14/220.5Review analysis from Company management and AlixPartnersThomas Melvin03/14/220.5Review analysis from Company management and AlixPartners regarding business developmentThomas Melvin03/14/22 <td< td=""><td></td><td></td><td></td><td></td></td<>				
Thomas Melvin03/07/220.5Call with Company management and AlixPartners regarding pipeline productsThomas Melvin03/08/221.0Board Special Committee meetingThomas Melvin03/08/221.0Review financial analysis related to Board requestThomas Melvin03/08/220.5Call with J. Turner to discuss various mattersThomas Melvin03/09/221.0Dialed into court hearingThomas Melvin03/10/221.0Weekly update call with Company management and debtor advisorsThomas Melvin03/10/221.0Dialed into court hearingThomas Melvin03/11/221.0Call with Company management and AlixPartners regarding public health initiative productsThomas Melvin03/11/220.5Call with internal team to discuss various mattersThomas Melvin03/11/220.5Review financial analysis from Company managementThomas Melvin03/11/220.5E-mail correspondence with AlixPartners and Company management regarding various mattersThomas Melvin03/11/220.5Review analysis from Company management and AlixPartnersThomas Melvin03/13/220.5Review analysis from Company management and AlixPartners regarding business developmentThomas Melvin03/14/220.5Review agenda for weekly creditor financial advisor discussionThomas Melvin03/14/220.5Review Analysis from DPWThomas Melvin03/14/220.5Review Analysis from DPWThomas Melvin03/14/220.5Review analysis and other matters<				
Thomas Melvin03/08/221.0Board Special Committee meetingThomas Melvin03/08/221.0Review financial analysis related to Board requestThomas Melvin03/08/220.5Call with J. Turner to discuss various mattersThomas Melvin03/09/221.0Dialed into court hearingThomas Melvin03/10/221.0Weekly update call with Company management and debtor advisorsThomas Melvin03/10/221.0Dialed into court hearingThomas Melvin03/11/221.0Call with Company management and AlixPartners regarding public health initiative productsThomas Melvin03/11/220.5Call with Company management and AlixPartners regarding public health initiative productsThomas Melvin03/11/220.5Review financial analysis from Company managementThomas Melvin03/11/220.5Review AlixPartners analysisThomas Melvin03/11/220.5E-mail correspondence with AlixPartners and Company management regarding various mattersThomas Melvin03/11/220.5Call with AlixPartners to discuss various mattersThomas Melvin03/13/221.5Review analysis from Company management and AlixPartnersThomas Melvin03/14/220.5Review analysis from Company management and AlixPartnersThomas Melvin03/14/220.5Review Analysis from AlixPartners and Company managementThomas Melvin03/14/220.5Review time estimates from DPWThomas Melvin03/14/220.5Review and prepare agenda for weekly discussio				
Thomas Melvin03/08/221.0Review financial analysis related to Board requestThomas Melvin03/08/220.5Call with J. Turner to discuss various mattersThomas Melvin03/09/221.0Dialed into court hearingThomas Melvin03/10/221.0Weekly update call with Company management and debtor advisorsThomas Melvin03/10/221.0Dialed into court hearingThomas Melvin03/11/221.0Call with Company management and AlixPartners regarding public health initiative productsThomas Melvin03/11/220.5Call with internal team to discuss various mattersThomas Melvin03/11/220.5Review financial analysis from Company managementThomas Melvin03/11/220.5Review AlixPartners analysisThomas Melvin03/11/220.5E-mail correspondence with AlixPartners and Company management regarding various mattersThomas Melvin03/11/220.5Call with AlixPartners to discuss various mattersThomas Melvin03/13/221.5Review analysis from Company management and AlixPartnersThomas Melvin03/13/221.5Review agenda for weekly creditor financial advisor discussionThomas Melvin03/14/221.0Call with Company management and AlixPartners regarding business developmentThomas Melvin03/14/220.5Review Analysis from AlixPartners and Company managementThomas Melvin03/14/220.5Review and prepare agenda for weekly discussion with creditor financial advisorsThomas Melvin03/14/22				
Thomas Melvin03/08/220.5Call with J. Turner to discuss various mattersThomas Melvin03/09/221.0Dialed into court hearingThomas Melvin03/10/221.0Weekly update call with Company management and debtor advisorsThomas Melvin03/10/221.0Dialed into court hearingThomas Melvin03/11/221.0Call with Company management and AlixPartners regarding public health initiative productsThomas Melvin03/11/220.5Call with internal team to discuss various mattersThomas Melvin03/11/221.5Review financial analysis from Company managementThomas Melvin03/11/220.5Review AlixPartners analysisThomas Melvin03/11/220.5E-mail correspondence with AlixPartners and Company management regarding various mattersThomas Melvin03/11/220.5Call with AlixPartners to discuss various mattersThomas Melvin03/13/221.5Review analysis from Company management and AlixPartnersThomas Melvin03/13/220.5Review agenda for weekly creditor financial advisor discussionThomas Melvin03/14/221.0Call with Company management and AlixPartners regarding business developmentThomas Melvin03/14/220.5Review Analysis from AlixPartners and Company managementThomas Melvin03/14/220.5Review Analysis from AlixPartners and Company managementThomas Melvin03/14/220.5Review agenda for weekly discussion with creditor financial advisorsThomas Melvin03/15/220.				
Thomas Melvin03/09/221.0Dialed into court hearingThomas Melvin03/10/221.0Weekly update call with Company management and debtor advisorsThomas Melvin03/10/221.0Dialed into court hearingThomas Melvin03/11/221.0Call with Company management and AlixPartners regarding public health initiative productsThomas Melvin03/11/220.5Call with internal team to discuss various mattersThomas Melvin03/11/221.5Review financial analysis from Company managementThomas Melvin03/11/220.5Review AlixPartners analysisThomas Melvin03/11/220.5E-mail correspondence with AlixPartners and Company management regarding various mattersThomas Melvin03/11/220.5Call with AlixPartners to discuss various mattersThomas Melvin03/13/221.5Review analysis from Company management and AlixPartnersThomas Melvin03/13/220.5Review agenda for weekly creditor financial advisor discussionThomas Melvin03/14/221.0Call with Company management and AlixPartners regarding business developmentThomas Melvin03/14/222.0Review Analysis from AlixPartners and Company managementThomas Melvin03/14/220.5Review Analysis from DPWThomas Melvin03/14/220.5Review timeline estimates from DPWThomas Melvin03/14/220.5Call with AlixPartners to discuss analysis and other mattersThomas Melvin03/15/220.5Call with Company management and AlixPartn				
Thomas Melvin03/10/221.0Weekly update call with Company management and debtor advisorsThomas Melvin03/10/221.0Dialed into court hearingThomas Melvin03/11/221.0Call with Company management and AlixPartners regarding public health initiative productsThomas Melvin03/11/220.5Call with internal team to discuss various mattersThomas Melvin03/11/221.5Review financial analysis from Company managementThomas Melvin03/11/220.5Review AlixPartners analysisThomas Melvin03/11/220.5E-mail correspondence with AlixPartners and Company management regarding various mattersThomas Melvin03/11/220.5Call with AlixPartners to discuss various mattersThomas Melvin03/13/221.5Review analysis from Company management and AlixPartnersThomas Melvin03/13/220.5Review agenda for weekly creditor financial advisor discussionThomas Melvin03/14/220.5Review agenda for weekly creditor financial advisor discussionThomas Melvin03/14/220.5Review Analysis from AlixPartners and Company managementThomas Melvin03/14/220.5Review Analysis from AlixPartners and Company managementThomas Melvin03/14/220.5Review timeline estimates from DPWThomas Melvin03/14/220.5Review and prepare agenda for weekly discussion with creditor financial advisorsThomas Melvin03/15/220.5Call with Company management and AlixPartners regarding public health initiative products <td></td> <td></td> <td></td> <td></td>				
Thomas Melvin 03/10/22 1.0 Dialed into court hearing Thomas Melvin 03/11/22 1.0 Call with Company management and AlixPartners regarding public health initiative products Thomas Melvin 03/11/22 0.5 Call with internal team to discuss various matters Thomas Melvin 03/11/22 1.5 Review financial analysis from Company management Thomas Melvin 03/11/22 0.5 Review AlixPartners analysis Thomas Melvin 03/11/22 0.5 E-mail correspondence with AlixPartners and Company management regarding various matters Thomas Melvin 03/11/22 0.5 Call with AlixPartners to discuss various matters Thomas Melvin 03/13/22 1.5 Review analysis from Company management and AlixPartners Thomas Melvin 03/13/22 0.5 Review agenda for weekly creditor financial advisor discussion Thomas Melvin 03/14/22 1.0 Call with Company management and AlixPartners regarding business development Thomas Melvin 03/14/22 2.0 Review Analysis from AlixPartners and Company management Thomas Melvin 03/14/22 0.5 Review Analysis from AlixPartners and Company management Thomas Melvin 03/14/22 0.5 Review and prepare agenda for weekly discussion with creditor financial advisors Thomas Melvin 03/14/22 0.5 Review and prepare agenda for weekly discussion with creditor financial advisors Thomas Melvin 03/14/22 0.5 Call with AlixPartners to discuss analysis and other matters Thomas Melvin 03/15/22 0.5 Call with AlixPartners to discuss analysis and other matters Thomas Melvin 03/15/22 1.0 Weekly update call with creditor financial advisors Thomas Melvin 03/15/22 1.0 Weekly update call with creditor financial advisors				
Thomas Melvin 03/11/22 0.5 Call with Company management and AlixPartners regarding public health initiative products Thomas Melvin 03/11/22 1.5 Review financial analysis from Company management Thomas Melvin 03/11/22 0.5 Review AlixPartners analysis Thomas Melvin 03/11/22 0.5 E-mail correspondence with AlixPartners and Company management regarding various matters Thomas Melvin 03/11/22 0.5 Call with AlixPartners to discuss various matters Thomas Melvin 03/13/22 1.5 Review analysis from Company management and AlixPartners Thomas Melvin 03/13/22 1.5 Review analysis from Company management and AlixPartners Thomas Melvin 03/13/22 1.5 Review agenda for weekly creditor financial advisor discussion Thomas Melvin 03/14/22 1.0 Call with Company management and AlixPartners regarding business development Thomas Melvin 03/14/22 2.0 Review Analysis from AlixPartners and Company management Thomas Melvin 03/14/22 0.5 Review timeline estimates from DPW Thomas Melvin 03/14/22 0.5 Review and prepare agenda for weekly discussion with creditor financial advisors Thomas Melvin 03/14/22 0.5 Call with AlixPartners to discuss analysis and other matters Thomas Melvin 03/15/22 0.5 Call with Company management and AlixPartners regarding public health initiative products Thomas Melvin 03/15/22 1.0 Weekly update call with creditor financial advisors Thomas Melvin 03/15/22 1.0 Weekly update call with creditor financial advisors				
Thomas Melvin03/11/220.5Call with internal team to discuss various mattersThomas Melvin03/11/221.5Review financial analysis from Company managementThomas Melvin03/11/220.5Review AlixPartners analysisThomas Melvin03/11/220.5E-mail correspondence with AlixPartners and Company management regarding various mattersThomas Melvin03/11/220.5Call with AlixPartners to discuss various mattersThomas Melvin03/13/221.5Review analysis from Company management and AlixPartnersThomas Melvin03/13/220.5Review agenda for weekly creditor financial advisor discussionThomas Melvin03/14/221.0Call with Company management and AlixPartners regarding business developmentThomas Melvin03/14/222.0Review Analysis from AlixPartners and Company managementThomas Melvin03/14/220.5Review Analysis from DPWThomas Melvin03/14/220.5Review and prepare agenda for weekly discussion with creditor financial advisorsThomas Melvin03/14/220.5Call with AlixPartners to discuss analysis and other mattersThomas Melvin03/15/220.5Call with Company management and AlixPartners regarding public health initiative productsThomas Melvin03/15/221.0Weekly update call with creditor financial advisorsThomas Melvin03/15/221.0Weekly update call with creditor financial advisors	Thomas Melvin	03/11/22		
Thomas Melvin 03/11/22 0.5 Review AlixPartners analysis Thomas Melvin 03/11/22 0.5 E-mail correspondence with AlixPartners and Company management regarding various matters Thomas Melvin 03/11/22 0.5 Call with AlixPartners to discuss various matters Thomas Melvin 03/13/22 1.5 Review analysis from Company management and AlixPartners Thomas Melvin 03/13/22 0.5 Review agenda for weekly creditor financial advisor discussion Thomas Melvin 03/14/22 1.0 Call with Company management and AlixPartners regarding business development Thomas Melvin 03/14/22 2.0 Review Analysis from AlixPartners and Company management Thomas Melvin 03/14/22 0.5 Review timeline estimates from DPW Thomas Melvin 03/14/22 0.5 Review and prepare agenda for weekly discussion with creditor financial advisors Thomas Melvin 03/14/22 0.5 Call with AlixPartners to discuss analysis and other matters Thomas Melvin 03/15/22 0.5 Call with Company management and AlixPartners regarding public health initiative products Thomas Melvin 03/15/22 1.0 Weekly update call with creditor financial advisors Thomas Melvin 03/15/22 1.0 Weekly update call with company management, AlixPartners and DPW to discuss various matters	Thomas Melvin	03/11/22	0.5	
Thomas Melvin 03/11/22 0.5 Review AlixPartners analysis  Thomas Melvin 03/11/22 0.5 E-mail correspondence with AlixPartners and Company management regarding various matters  Thomas Melvin 03/11/22 0.5 Call with AlixPartners to discuss various matters  Thomas Melvin 03/13/22 1.5 Review analysis from Company management and AlixPartners  Thomas Melvin 03/13/22 0.5 Review agenda for weekly creditor financial advisor discussion  Thomas Melvin 03/14/22 1.0 Call with Company management and AlixPartners regarding business development  Thomas Melvin 03/14/22 2.0 Review Analysis from AlixPartners and Company management  Thomas Melvin 03/14/22 0.5 Review timeline estimates from DPW  Thomas Melvin 03/14/22 0.5 Review and prepare agenda for weekly discussion with creditor financial advisors  Thomas Melvin 03/14/22 0.5 Call with AlixPartners to discuss analysis and other matters  Thomas Melvin 03/15/22 0.5 Call with Company management and AlixPartners regarding public health initiative products  Thomas Melvin 03/15/22 1.0 Weekly update call with creditor financial advisors  Thomas Melvin 03/15/22 1.0 Call with Company management, AlixPartners and DPW to discuss various matters	Thomas Melvin	03/11/22	1.5	Review financial analysis from Company management
Thomas Melvin 03/11/22 0.5 Call with AlixPartners to discuss various matters  Thomas Melvin 03/13/22 1.5 Review analysis from Company management and AlixPartners  Thomas Melvin 03/13/22 0.5 Review agenda for weekly creditor financial advisor discussion  Thomas Melvin 03/14/22 1.0 Call with Company management and AlixPartners regarding business development  Thomas Melvin 03/14/22 2.0 Review Analysis from AlixPartners and Company management  Thomas Melvin 03/14/22 0.5 Review timeline estimates from DPW  Thomas Melvin 03/14/22 0.5 Review and prepare agenda for weekly discussion with creditor financial advisors  Thomas Melvin 03/14/22 0.5 Call with AlixPartners to discuss analysis and other matters  Thomas Melvin 03/15/22 0.5 Call with Company management and AlixPartners regarding public health initiative products  Thomas Melvin 03/15/22 1.0 Weekly update call with creditor financial advisors  Thomas Melvin 03/15/22 1.0 Call with Company management, AlixPartners and DPW to discuss various matters	Thomas Melvin	03/11/22	0.5	
Thomas Melvin 03/11/22 0.5 Call with AlixPartners to discuss various matters  Thomas Melvin 03/13/22 1.5 Review analysis from Company management and AlixPartners  Thomas Melvin 03/13/22 0.5 Review agenda for weekly creditor financial advisor discussion  Thomas Melvin 03/14/22 1.0 Call with Company management and AlixPartners regarding business development  Thomas Melvin 03/14/22 2.0 Review Analysis from AlixPartners and Company management  Thomas Melvin 03/14/22 0.5 Review timeline estimates from DPW  Thomas Melvin 03/14/22 0.5 Review and prepare agenda for weekly discussion with creditor financial advisors  Thomas Melvin 03/14/22 0.5 Call with AlixPartners to discuss analysis and other matters  Thomas Melvin 03/15/22 0.5 Call with Company management and AlixPartners regarding public health initiative products  Thomas Melvin 03/15/22 1.0 Weekly update call with creditor financial advisors  Thomas Melvin 03/15/22 1.0 Call with Company management, AlixPartners and DPW to discuss various matters	Thomas Melvin	03/11/22	0.5	E-mail correspondence with AlixPartners and Company management regarding various matters
Thomas Melvin 03/13/22 0.5 Review agenda for weekly creditor financial advisor discussion  Thomas Melvin 03/14/22 1.0 Call with Company management and AlixPartners regarding business development  Thomas Melvin 03/14/22 2.0 Review Analysis from AlixPartners and Company management  Thomas Melvin 03/14/22 0.5 Review timeline estimates from DPW  Thomas Melvin 03/14/22 0.5 Review and prepare agenda for weekly discussion with creditor financial advisors  Thomas Melvin 03/14/22 0.5 Call with AlixPartners to discuss analysis and other matters  Thomas Melvin 03/15/22 0.5 Call with Company management and AlixPartners regarding public health initiative products  Thomas Melvin 03/15/22 1.0 Weekly update call with creditor financial advisors  Thomas Melvin 03/15/22 1.0 Call with Company management, AlixPartners and DPW to discuss various matters	Thomas Melvin	03/11/22	0.5	
Thomas Melvin 03/14/22 1.0 Call with Company management and AlixPartners regarding business development Thomas Melvin 03/14/22 2.0 Review Analysis from AlixPartners and Company management Thomas Melvin 03/14/22 0.5 Review timeline estimates from DPW Thomas Melvin 03/14/22 0.5 Review and prepare agenda for weekly discussion with creditor financial advisors Thomas Melvin 03/14/22 0.5 Call with AlixPartners to discuss analysis and other matters Thomas Melvin 03/15/22 0.5 Call with Company management and AlixPartners regarding public health initiative products Thomas Melvin 03/15/22 1.0 Weekly update call with creditor financial advisors Thomas Melvin 03/15/22 1.0 Call with Company management, AlixPartners and DPW to discuss various matters	Thomas Melvin	03/13/22	1.5	Review analysis from Company management and AlixPartners
Thomas Melvin 03/14/22 2.0 Review Analysis from AlixPartners and Company management Thomas Melvin 03/14/22 0.5 Review timeline estimates from DPW Thomas Melvin 03/14/22 0.5 Review and prepare agenda for weekly discussion with creditor financial advisors Thomas Melvin 03/14/22 0.5 Call with AlixPartners to discuss analysis and other matters Thomas Melvin 03/15/22 0.5 Call with Company management and AlixPartners regarding public health initiative products Thomas Melvin 03/15/22 1.0 Weekly update call with creditor financial advisors Thomas Melvin 03/15/22 1.0 Call with Company management, AlixPartners and DPW to discuss various matters	Thomas Melvin	03/13/22	0.5	Review agenda for weekly creditor financial advisor discussion
Thomas Melvin 03/14/22 0.5 Review timeline estimates from DPW  Thomas Melvin 03/14/22 0.5 Review and prepare agenda for weekly discussion with creditor financial advisors  Thomas Melvin 03/14/22 0.5 Call with AlixPartners to discuss analysis and other matters  Thomas Melvin 03/15/22 0.5 Call with Company management and AlixPartners regarding public health initiative products  Thomas Melvin 03/15/22 1.0 Weekly update call with creditor financial advisors  Thomas Melvin 03/15/22 1.0 Call with Company management, AlixPartners and DPW to discuss various matters	Thomas Melvin	03/14/22	1.0	Call with Company management and AlixPartners regarding business development
Thomas Melvin 03/14/22 0.5 Review and prepare agenda for weekly discussion with creditor financial advisors Thomas Melvin 03/14/22 0.5 Call with AlixPartners to discuss analysis and other matters Thomas Melvin 03/15/22 0.5 Call with Company management and AlixPartners regarding public health initiative products Thomas Melvin 03/15/22 1.0 Weekly update call with creditor financial advisors Thomas Melvin 03/15/22 1.0 Call with Company management, AlixPartners and DPW to discuss various matters	Thomas Melvin	03/14/22	2.0	Review Analysis from AlixPartners and Company management
Thomas Melvin 03/14/22 0.5 Call with AlixPartners to discuss analysis and other matters  Thomas Melvin 03/15/22 0.5 Call with Company management and AlixPartners regarding public health initiative products  Thomas Melvin 03/15/22 1.0 Weekly update call with creditor financial advisors  Thomas Melvin 03/15/22 1.0 Call with Company management, AlixPartners and DPW to discuss various matters	Thomas Melvin	03/14/22	0.5	
Thomas Melvin 03/15/22 0.5 Call with Company management and AlixPartners regarding public health initiative products Thomas Melvin 03/15/22 1.0 Weekly update call with creditor financial advisors Thomas Melvin 03/15/22 1.0 Call with Company management, AlixPartners and DPW to discuss various matters	Thomas Melvin	03/14/22	0.5	
Thomas Melvin 03/15/22 1.0 Weekly update call with creditor financial advisors Thomas Melvin 03/15/22 1.0 Call with Company management, AlixPartners and DPW to discuss various matters	Thomas Melvin	03/14/22	0.5	Call with AlixPartners to discuss analysis and other matters
Thomas Melvin 03/15/22 1.0 Call with Company management, AlixPartners and DPW to discuss various matters	Thomas Melvin	03/15/22	0.5	Call with Company management and AlixPartners regarding public health initiative products
	Thomas Melvin	03/15/22	1.0	Weekly update call with creditor financial advisors
Thomas Melvin 03/16/22 0.5 Call with Company management to discuss financial analysis	Thomas Melvin	03/15/22	1.0	
	Thomas Melvin	03/16/22	0.5	Call with Company management to discuss financial analysis

# 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 39 of 50 PJT PARTNERS LP

Professional	Date	Hours	Explanation
Thomas Melvin	03/16/22	0.5	Call with Company management to discuss business development
Thomas Melvin	03/16/22	0.5	E-mail correspondence with AlixPartners and Company management regarding various matters
Thomas Melvin	03/17/22	1.0	Weekly update call with Company management and debtor advisors
Thomas Melvin	03/17/22	0.5	E-mail correspondence with AlixPartners and Company management regarding various matters
Thomas Melvin	03/17/22	1.5	Review analysis from Company management and AlixPartners
Thomas Melvin	03/18/22	1.0	Call with Company management and AlixPartners to discuss public health initiatives
Thomas Melvin	03/18/22	1.0	Call with Company management, AlixPartners and DPW to discuss various matters
Thomas Melvin	03/18/22	1.5	Review analysis from Company management and AlixPartners
Thomas Melvin	03/18/22	0.5	E-mail correspondence with Company management and AlixPartners regarding various matters
Thomas Melvin	03/19/22	1.0	Review AlixPartners analysis
Thomas Melvin	03/19/22	0.5	Review materials from DPW
Thomas Melvin	03/19/22	0.5	E-mail correspondence with DPW and AlixPartners regarding presentation for upcoming meeting
Thomas Melvin	03/20/22	1.5	Review commentary from DPW, AlixPartners and Company management related to presentation draft
Thomas Melvin	03/20/22	1.0	Perform analysis in response to request from DPW
Thomas Melvin	03/20/22	0.5	E-mail correspondence with DPW and AlixPartners regarding various matters
Thomas Melvin	03/21/22	1.0	Review analysis form Company management and AlixPartners
Thomas Melvin	03/21/22	0.5	E-mail correspondence with Company management regarding various matters
Thomas Melvin	03/23/22	1.0	Call with Company management and AlixPartners to discuss public health initiatives
Thomas Melvin	03/23/22	1.0	Review analysis responsive to Board request
Thomas Melvin	03/24/22	1.0	Weekly update call with Company management and debtor advisors
Thomas Melvin	03/24/22	1.0	Call with Company management and AlixPartners to discuss pipeline products
Thomas Melvin	03/24/22	0.5	Call with internal team to discuss various matters
Thomas Melvin	03/28/22	0.5	Call with creditor financial advisors to discuss pipeline products
Thomas Melvin	03/28/22	0.5	Call with Company management regarding various matters
Thomas Melvin	03/28/22	1.0	Prepare and review analysis related to creditor financial advisor questions and requests
Thomas Melvin	03/28/22	1.0	Review analysis responsive to Board request
Thomas Melvin	03/29/22	0.5	Review agenda for weekly creditor financial advisor discussion
Thomas Melvin	03/29/22	1.0	Weekly update call with creditor financial advisors
Thomas Melvin	03/29/22	1.0	E-mail correspondence with AlixPartners and DPW regarding various matters
Thomas Melvin	03/30/22	0.5	Call with internal team to discuss various matters
Thomas Melvin	03/30/22	1.0	Perform and review analysis requested by Company management
Thomas Melvin	03/30/22	1.5	Review analysis responsive to Board request
Thomas Melvin	03/30/22	0.5	E-mail correspondence with AlixPartners and Company management regarding upcoming meetings

# 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 40 of 50 PJT PARTNERS LP

Professional	Date	Hours	Explanation
Thomas Melvin	03/31/22	3.5 <b>60.5</b>	Board meeting

# 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 41 of 50 PJT PARTNERS LP

Professional	Date	Hours	Explanation
Jovana Arsic	03/03/22	1.0	Weekly update call with management and advisors
		1.0	

# 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 42 of 50 PJT PARTNERS LP

Professional	Date	Hours	Explanation
Lukas Schwarzmann	03/03/22	1.0	Biweekly call
Lukas Schwarzmann	03/08/22	6.0	Financial analysis
Lukas Schwarzmann	03/09/22	5.0	Financial analysis
Lukas Schwarzmann	03/10/22	1.0	Biweekly call
Lukas Schwarzmann	03/14/22	1.0	Call with management
Lukas Schwarzmann	03/17/22	1.0	Biweekly call
Lukas Schwarzmann	03/20/22	5.0	Financial analysis
Lukas Schwarzmann	03/23/22	3.0	Financial analysis
Lukas Schwarzmann	03/24/22	2.0	Financial analysis
Lukas Schwarzmann	03/24/22	1.0	Biweekly call
Lukas Schwarzmann	03/24/22	0.5	Internal catch-up call
Lukas Schwarzmann	03/28/22	2.0	Financial analysis
Lukas Schwarzmann	03/29/22	2.0	Financial analysis
Lukas Schwarzmann	03/30/22	2.0	Financial analysis
Lukas Schwarzmann	03/31/22	3.0	Financial analysis
		35.5	

# 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 43 of 50 PJT PARTNERS LP

## SUMMARY OF HOURS FOR THE PERIOD OF APRIL 1, 2022 THROUGH APRIL 30, 2022

Professional	Title	Hours
Jamie O'Connell	Partner	7.5
Rafael Schnitzler	Managing Director	14.5
Tom Melvin	Vice President	108.5
Lukas Schwarzmann	Analyst	43.5
	Total	<u>174.0</u>

## 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 44 of 50

## PJT PARTNERS LP

Professional	Date	Hours	Explanation
Jamie O'Connell	04/01/22	0.5	Call with T. Melvin to discuss various matters
Jamie O'Connell	04/05/22	0.5	Call with T. Melvin to discuss various matters
Jamie O'Connell	04/05/22	0.5	Special Committee call
Jamie O'Connell	04/07/22	0.5	Weekly update call with Company and advisors
Jamie O'Connell	04/11/22	0.5	Call with T. Melvin to discuss various matters
Jamie O'Connell	04/14/22	0.5	Weekly update call with Company and advisors
Jamie O'Connell	04/19/22	0.5	Meeting with PJT team regarding financial matter
Jamie O'Connell	04/21/22	1.0	Weekly update call with Company and advisors
Jamie O'Connell	04/25/22	0.5	Call with Company management to discuss various matters
Jamie O'Connell	04/26/22	1.0	Meeting with PJT team regarding financial matter
Jamie O'Connell	04/26/22	1.0	Call with Company management to discuss various matters
Jamie O'Connell	04/28/22	0.5	Call with DPW regarding various matters
		7.5	

# 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 45 of 50 PJT PARTNERS LP

Professional	Date	Hours	Explanation
Rafael Schnitzler	04/01/22	0.5	Conference call with Company and AlixPartners regarding business matters
Rafael Schnitzler	04/01/22	1.0	Conference call with creditor financial advisors to discuss business development strategy
Rafael Schnitzler	04/06/22	1.0	Prepare materials requested by AlixPartners and DPW
Rafael Schnitzler	04/07/22	1.0	Weekly update call with Company management and debtor advisors
Rafael Schnitzler	04/08/22	0.5	Conference call with Company management to discuss business development opportunity
Rafael Schnitzler	04/11/22	1.0	Prepare materials requested by AlixPartners and DPW
Rafael Schnitzler	04/12/22	0.5	Call with T. Melvin to discuss upcoming meeting
Rafael Schnitzler	04/14/22	1.0	Weekly update call with Company management and debtor advisors
Rafael Schnitzler	04/14/22	0.5	Respond to questions from AlixPartners and DPW
Rafael Schnitzler	04/18/22	0.5	Conference call with AlixPartners to prepare for upcoming meetings
Rafael Schnitzler	04/18/22	1.0	Prepare materials requested by AlixPartners and Company management
Rafael Schnitzler	04/19/22	0.5	Internal team call to prepare for upcoming meeting
Rafael Schnitzler	04/19/22	0.5	Review and edit material requested by Company management
Rafael Schnitzler	04/20/22	1.0	Conference call with Company management and AlixPartners to discuss business development opportunity
Rafael Schnitzler	04/21/22	1.0	Weekly update call with Company management and debtor advisors
Rafael Schnitzler	04/26/22	0.5	Meeting with internal team regarding business development opportunity
Rafael Schnitzler	04/26/22	1.0	Analyze certain business lines related to possible business development opportunities
Rafael Schnitzler	04/28/22	1.0	Weekly update call with Company management and debtor advisors
Rafael Schnitzler	04/28/22	0.5	Prepare draft document requested by Company management
		14.5	

# 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 46 of 50 PJT PARTNERS LP

Professional	Date	Hours	Explanation
Thomas Melvin	04/01/22	0.5	Call with Company management, DPW and AlixPartners regarding various strategic matters
Thomas Melvin	04/01/22	1.0	Call with AlixPartners and creditor financial advisors regarding certain business matters
Thomas Melvin	04/01/22	0.5	Call with internal team regarding various matters
Thomas Melvin	04/01/22	0.5	Call with AlixPartners regarding various matters
Thomas Melvin	04/01/22	0.5	Call with internal team regarding financial analysis
Thomas Melvin	04/01/22	1.5	E-mail correspondence with Company management and AlixPartners regarding various matters
Thomas Melvin	04/02/22	0.5	E-mail correspondence with DPW regarding creditor advisor requests
Thomas Melvin	04/04/22	2.0	Review and respond to requests from creditor financial advisors
Thomas Melvin	04/04/22	0.5	Call with internal team to discuss various matters
Thomas Melvin	04/04/22	1.0	E-mail correspondence with AlixPartners and Company management regarding various matters
Thomas Melvin	04/05/22	1.0	Attended Board Special Committee meeting
Thomas Melvin	04/05/22	0.5	Call with AlixPartners to discuss various matters
Thomas Melvin	04/05/22	2.0	Prepare response to request from Company management
Thomas Melvin	04/05/22	1.0	Review materials prepared by AlixPartners
Thomas Melvin	04/05/22	1.0	E-mail correspondence with AlixPartners and Company management regarding various matters
Thomas Melvin	04/05/22	0.5	E-mail correspondence with internal team related to various matters
Thomas Melvin	04/06/22	0.5	Call with Company management regarding business development opportunity
Thomas Melvin	04/06/22	1.5	Prepare response to request from Company management
Thomas Melvin	04/06/22	3.0	Review and respond to requests from creditor financial advisors
Thomas Melvin	04/06/22	1.5	E-mail correspondence with AlixPartners and Company management regarding various matters
Thomas Melvin	04/06/22	0.5	Research related to diligence materials
Thomas Melvin	04/06/22	0.5	Prepare and review agenda for weekly update call
Thomas Melvin	04/07/22	1.0	Weekly update call with Company management and debtor advisors
Thomas Melvin	04/07/22	1.0	Perform research related to business development opportunity
Thomas Melvin	04/07/22	1.5	E-mail correspondence with AlixPartners, Company management and DPW regarding various matters
Thomas Melvin	04/07/22	1.5	Review materials identified by AlixPartners in response to request from Company management
Thomas Melvin	04/07/22	1.0	Review and respond to requests from creditor financial advisors
Thomas Melvin	04/07/22	0.5	Call with Company management to discuss business development opportunity
Thomas Melvin	04/08/22	0.5	Call with Company management and AlixPartners regarding business strategy
Thomas Melvin	04/08/22	1.0	Review requests from creditor financial advisors
Thomas Melvin	04/08/22	1.0	E-mail correspondence with AlixPartners and creditor financial advisors regarding diligence materials
Thomas Melvin	04/09/22	1.0	E-mail correspondence with creditor financial advisors and AlixPartners regarding various matters
Thomas Melvin	04/09/22	1.0	Prepare materials requested by Company management
Thomas Melvin	04/11/22	2.0	Prepare materials requested by Company management
Thomas Melvin	04/11/22	1.0	Aggregate and review materials requested by creditor advisors

# 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 47 of 50 PJT PARTNERS LP

Professional	Date	Hours	Explanation
Thomas Melvin	04/11/22	0.5	Call with AlixPartners to discuss various matters
Thomas Melvin	04/11/22	0.5	Call with internal team regarding various matters
Thomas Melvin	04/11/22	1.0	E-mail correspondence with AlixPartners and Company management regarding various matters
Thomas Melvin	04/12/22	1.0	Weekly call with AlixPartners and creditor financial advisors
Thomas Melvin	04/12/22	0.5	Call with internal team member regarding upcoming meetings
Thomas Melvin	04/12/22	1.0	Prepare materials requested by Company management
Thomas Melvin	04/12/22	1.0	Review materials for upcoming meetings
Thomas Melvin	04/12/22	1.0	Prepare and review materials for creditor financial advisors
Thomas Melvin	04/12/22	1.0	E-mail correspondence with DPW, AlixPartners and Company management regarding various matters
Thomas Melvin	04/13/22	1.0	Call with AlixPartners and DPW regarding intellectual property
Thomas Melvin	04/13/22	1.0	Prepare materials requested by Company management
Thomas Melvin	04/13/22	0.5	Call with internal team regarding various analyses
Thomas Melvin	04/13/22	1.0	Review AlixPartners analysis
Thomas Melvin	04/13/22	0.5	E-mail correspondence with DPW and AlixPartners regarding various matters
Thomas Melvin	04/14/22	1.0	Weekly update call with Company management and debtor advisors
Thomas Melvin	04/14/22	1.5	E-mail correspondence with AlixPartners, DPW and Company management regarding various matters
Thomas Melvin	04/14/22	2.0	Review materials from Company management related to business development activities
Thomas Melvin	04/14/22	1.0	Review and respond to questions from Company management and DPW
Thomas Melvin	04/14/22	1.0	Review requests from creditor financial advisors
Thomas Melvin	04/15/22	0.5	Call with internal team member to discuss various matters
Thomas Melvin	04/15/22	1.5	Review questions from creditor advisors
Thomas Melvin	04/16/22	1.5	Review materials from Company management related to business development activities
Thomas Melvin	04/16/22	0.5	E-mail correspondence with Company management regarding various matters
Thomas Melvin	04/17/22	1.0	Review materials from Company management related to business development activities
Thomas Melvin	04/17/22	1.5	E-mail correspondence with Company management related to upcoming meetings
Thomas Melvin	04/18/22	0.5	Call with AlixPartners to discuss business development opportunities
Thomas Melvin	04/18/22	1.0	Review materials from Company management related to business development activities
Thomas Melvin	04/18/22	1.0	E-mail correspondence with Company management and AlixPartners related to upcoming meetings
Thomas Melvin	04/18/22	0.5	E-mail correspondence with internal team related to various matters
Thomas Melvin	04/18/22	1.5	Prepare materials requested by Company management
Thomas Melvin	04/18/22	1.0	Review AlixPartners analysis
Thomas Melvin	04/19/22	0.5	Call with internal team regarding business development opportunities
Thomas Melvin	04/19/22	1.0	Prepare and review materials requested by Company management
Thomas Melvin	04/19/22	1.5	Review questions from and responses to creditor advisors
Thomas Melvin	04/19/22	1.5	Review materials from AlixPartners

# 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 48 of 50 PJT PARTNERS LP

Professional	Date	Hours	Explanation
		_	
Thomas Melvin	04/19/22	1.0	E-mail correspondence with AlixPartners and DPW regarding various matters
Thomas Melvin	04/20/22	1.0	Call with Company management and AlixPartners regarding business development opportunities
Thomas Melvin	04/20/22	1.0	Review materials from Company management related to business development activities
Thomas Melvin	04/20/22	0.5	Call with internal team regarding analysis
Thomas Melvin	04/20/22	1.0	Review materials prepared by AlixPartners
Thomas Melvin	04/20/22	1.0	E-mail correspondence with Company management and AlixPartners regarding diligence requests
Thomas Melvin	04/21/22	1.0	Weekly update call with Company management and debtor advisors
Thomas Melvin	04/22/22	1.0	Review AlixPartners analysis
Thomas Melvin	04/23/22	0.5	E-mail correspondence with creditor financial advisors and AlixPartners regarding various matters
Thomas Melvin	04/25/22	1.0	Review materials prepared by AlixPartners
Thomas Melvin	04/25/22	1.0	Prepare and review materials requested by Company management related to business development
Thomas Melvin	04/25/22	1.0	E-mail correspondence with internal team and Company management related to upcoming meetings
Thomas Melvin	04/26/22	0.5	Call with internal team regarding business development opportunity
Thomas Melvin	04/26/22	0.5	Call with Company management and AlixPartners regarding public health initiative products
Thomas Melvin	04/26/22	1.0	Weekly call with AlixPartners and creditor financial advisors
Thomas Melvin	04/26/22	1.5	Review materials prepared by management related to public health initiative products
Thomas Melvin	04/26/22	2.0	Review materials prepared by AlixPartners related to upcoming hearings
Thomas Melvin	04/26/22	1.0	Prepare and review analysis related to upcoming meetings
Thomas Melvin	04/26/22	1.5	Prepare and review materials requested by Company management
Thomas Melvin	04/27/22	3.0	Dialed into court hearing
Thomas Melvin	04/27/22	0.5	Call with AlixPartners to discuss various matters
Thomas Melvin	04/27/22	0.5	Call with internal team to discuss analysis
Thomas Melvin	04/27/22	1.0	Review materials from Company management related to business development activities
Thomas Melvin	04/27/22	1.5	E-mail correspondence with Company management and AlixPartners regarding various matters
Thomas Melvin	04/28/22	1.0	Weekly update call with Company management and debtor advisors
Thomas Melvin	04/28/22	0.5	Call with Company management regarding upcoming Board meeting
Thomas Melvin	04/28/22	3.0	Prepare slides for upcoming Board meeting
Thomas Melvin	04/28/22	0.5	Call with AlixPartners to discuss various matters
Thomas Melvin	04/28/22	0.5	Call with Company management regarding various matters
Thomas Melvin	04/28/22	0.5	Call with internal team to discuss various matters
Thomas Melvin	04/28/22	0.5	E-mail correspondence with AlixPartners regarding various matters
Thomas Melvin	04/29/22	2.0	Dialed into 2nd circuit oral arguments
Thomas Melvin	04/29/22	1.0	E-mail correspondence with Company management related to upcoming meetings
Thomas Melvin	04/29/22	1.0	Review materials prepared by AlixPartners
Thomas Melvin	04/29/22	1.0	Prepare and review materials requested by Company management related to business development

# 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 49 of 50 PJT PARTNERS LP

Professional	Date	Hours	Explanation
Thomas Melvin	04/29/22	1.0 108.5	Review draft document prepared by Company management

# 19-23649-shl Doc 4798 Filed 05/16/22 Entered 05/16/22 14:51:46 Main Document Pg 50 of 50 PJT PARTNERS LP

Professional	Date	Hours	Explanation
Lukas Schwarzmann	04/01/22	0.5	Conference call with Company and AlixPartners regarding business matters
Lukas Schwarzmann	04/01/22	1.0	Conference call with creditor financial advisors to discuss business development strategy
Lukas Schwarzmann	04/04/22	0.5	Call with internal team to discuss various matters
Lukas Schwarzmann	04/04/22	2.0	Financial analysis
Lukas Schwarzmann	04/05/22	3.0	Financial analysis
Lukas Schwarzmann	04/06/22	0.5	Call with Company regarding business matters
Lukas Schwarzmann	04/06/22	4.0	Financial analysis
Lukas Schwarzmann	04/07/22	1.0	Weekly update call with Company management and debtor advisors
Lukas Schwarzmann	04/08/22	0.5	Conference call with Company management to discuss business development opportunity
Lukas Schwarzmann	04/09/22	2.0	Financial analysis
Lukas Schwarzmann	04/11/22	0.5	Call with internal team to discuss various matters
Lukas Schwarzmann	04/11/22	3.0	Financial analysis
Lukas Schwarzmann	04/12/22	2.0	Financial analysis
Lukas Schwarzmann	04/13/22	0.5	Call with internal team regarding various analyses
Lukas Schwarzmann	04/13/22	1.0	Financial analysis
Lukas Schwarzmann	04/14/22	1.0	Weekly update call with Company management and debtor advisors
Lukas Schwarzmann	04/15/22	0.5	Call with internal team member to discuss various matters
Lukas Schwarzmann	04/15/22	3.0	Financial analysis
Lukas Schwarzmann	04/18/22	3.0	Financial analysis
Lukas Schwarzmann	04/18/22	0.5	Conference call with AlixPartners to prepare for upcoming meetings
Lukas Schwarzmann	04/19/22	0.5	Financial analysis
Lukas Schwarzmann	04/20/22	1.0	Conference call with Company management and AlixPartners to discuss business development opportunity
Lukas Schwarzmann	04/20/22	2.0	Financial analysis
Lukas Schwarzmann	04/20/22	0.5	Call with internal team regarding analysis
Lukas Schwarzmann	04/20/22	2.0	Financial analysis
Lukas Schwarzmann	04/21/22	1.0	Weekly update call with Company management and debtor advisors
Lukas Schwarzmann	04/21/22	1.0	Financial analysis
Lukas Schwarzmann	04/25/22	1.5	Financial analysis
Lukas Schwarzmann	04/26/22	0.5	Meeting with internal team regarding business development opportunity
Lukas Schwarzmann	04/26/22	0.5	Call with internal team regarding analysis
Lukas Schwarzmann	04/27/22	1.0	Financial analysis
Lukas Schwarzmann	04/28/22	1.0	Weekly update call with Company management and debtor advisors
Lukas Schwarzmann	04/28/22	0.5	Call with internal team to discuss various matters
Lukas Schwarzmann	04/28/22	0.5	Financial analysis
		43.5	